Stability Testing for Drug Substances and Drug Products
23/24 October 2024, Barcelona, Spain
Course No. 21464
Speakers
Dr. Cornelia Nopitsch-Mai
formerly Quality Assessor
Dr Thomas Uhlich
Bayer
Dr. Josef Hofer
exdra
Dr. Thomas Fürst
Boehringer Ingelheim
Dr. Heiko Brunner
Hamburg
Dr Ulli Backofen
Boehringer Ingelheim
Objectives
This event is intended to provide information on different aspects of stability testing. The conference will be opened by an overview of stability testing with a special focus on important changes in current revisions of ICH Guidelines. In the subsequent presentations, important aspects of stability testing for biologicals and throughout drug development are discussed. The second day commences with a lecture on stability testing for Drug Substances, followed by a talk on Drug Products and a risk based approach for stability testing covering different climatic zones. In the following presentation, the focus lies on to the various aspects of submitting stability data. The specific challenges of data evaluation and typical questions from authorities will also be addressed. Finally, statistical considerations will be covered in another lecture.
Background
Analytical methods that were not “stability-indicating” are frequently cited in FDA 483s and Warning Letters. This conference will thus address how to set impurity limits for related substances and degradation products based on method capability and stability results.
The analytical result, which will be compared to the specification, is affected by the variability of the measurement itself and depends also on the sampling process and on the variability of the manufacturing process of the tested product itself. This makes statistical considerations essential and consideration of the associated measurement uncertainties vital when setting or complying with specifications.
Finally, specifications for the API (drug substance), excipient(s) and the drug product are part of the quality section of the marketing authorisation application which has to be submitted to the competent authority.
Target Group
This conference is of particular interest to specialists from QA, QC and Regulatory Affairs departments of the API and pharmaceutical industry and CROs as well as to members of the EU inspectorates and authorities. Participants have the opportunity to exchange their experiences they gained with the different aspects of ‘specifications’ with the experts from the API and pharmaceutical industry as well as with members of competent authorities.
Testimonials
Seminar Programme as PDF